Evaluation of SpO2, PaO2, FiO2 levels in developing retinopathy of prematurity


  • Porimal Kumar Das Department of Paediatrics, Mugda Medical College Hospital, Mugda, Dhaka, Bangladesh
  • Shubhra Prakash Paul Department of Community Medicine, Rajshahi Medical College, Rajshahi, Bangladesh
  • Md Shamim Parvej Ibne Halim Department of Paediatrics, Mugda Medical College Hospital, Mugda, Dhaka, Bangladesh
  • Mohammad Abdullah Al Mamun Department of Paediatrics Cardiology, BICH and Dhaka Shishu (Children) Hospital, Dhaka, Bangladesh
  • Mohammad Monir Hossain Department of Neonatal Medicine and NICU, BICH and Dhaka Shishu (Children) Hospital, Dhaka, Bangladesh
  • Mahfuza Shirin Department of Neonatal Medicine and NICU, BICH and Dhaka Shishu (Children) Hospital, Dhaka, Bangladesh
  • A. H. M. Enayet Hossain Paediatric Ophthalmology, National Institute of Ophthalmology, Dhaka, Bangladesh
  • Puspanjali Biswas Department of Biochemistry, Dhaka Community Hospital, Dhaka, Bangladesh




SpO2, PaO2, FiO2 levels, Retinopathy, Prematurity, ROP


Background: Retinopathy of prematurity (ROP) is a potentially blinding disease affecting the retinas in premature infants. In the treatment procedure of ROP, oxygen inhalation as well as the SpO2, PaO2, FiO2 levels analysis are some major concerns.

Methods: This was a prospective COHORT study which was conducted at the special care baby unit (SCABU) and intensive care unit (ICU) of Dhaka shishu (children) hospital, Dhaka, Bangladesh from July 2012 to December 2014. Total one hundred (100) neonates of both sexes were finalized as the study population. Data were processed and analyzed using statistical software SPSS version 17, EPI info 7.

Results: Four neonates (12.50%) who developed ROP received (41-60)% oxygen in inhaled air and this concentration was we found statistically significant risk for ROP, RR 3.48 (2.61-4.64) but there was no risk associated with FiO2 (24-32)% or 33-40% in inhaled air. SpO2 (95-99)% was present in 25 (78.13%) of ROP (positive) neonates and 16 (23.53%) in ROP (negative) neonates. The difference was statistically significant (p<0.05) between the groups and RR 4.8 (2.51-9.28) for saturation of 95-99%. Partial pressure of oxygen >150 mm of Hg present in 12 (37.50%) cases of ROP (positive) neonates and 6 (8.82%) in ROP (negative) neonates. The difference was statistically significant (p<0.05) between the groups and RR 2.90 (1.83-4.5) for partial pressure of oxygen (>150) but there was no risk for partial pressure of 70-99 and 100-150 mm of Hg.

Conclusions: During oxygen therapy FiO2 value, SpO2 value and more precisely the PaO2 value on neonate should be maintained within a target range.


World Health Organization. Global Initiative for the Elimination of Avoidable Blindness: action plan 2006-2011. Available at: https://apps.who.int/iris/ handle/10665/43754. Accessed on 3 March 2021.

Walter JR. Retrolental Fibroplasia: a modern parable. J Pediatr Ophthalmol Strabismus. 1980;17(5):347.

Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens: I, preliminary report. Am J Ophthalmol. 2018;25:203-4.

Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia; a clinical approach. Med J Aust. 1951;2(2):48-50.

Gilbert C. Retinopathy of prematurity: Epidemiology. Comm Eye Health J. 1997;10(22):22-4.

Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84(2):77-82.

Courtright P, Hutchinson AK, Lewallen S. Visual impairment in children in middle- and lower-income countries. Arch Dis Child. 2011;96(12):1129-34.

Gilbert C, Rahi J, Eckstein M, O'Sullivan J, Foster A. Retinopathy of prematurity in middle-income countries. Lancet. 1997;350(9070):12-4.

McClom JR, Fleck BW. Retinopathy of prematurity: causation. Semin Neonatol. 2000;6(6):453-60.

Saugstad OD. Oxygen and retinopathy of prematurity. J Perinatol. 2006;26:46-50.

Sola A, Chow L, Rogido M. Retinopathy of prematurity and oxygen therapy: a changing relationship. An Pediatr (Barc). 2005;62(1):48-61.

Sola A, Rogido MR, Deulofeut R. Oxygen as a neonatal health hazard: call for détente in clinical practice. Acta Paediatrica. 2007;96(6):801-12.

McGregor ML, Bremer DL, Cole C, McClead RE, Phelps DL, Fellows RR, et al. Retinopathy of Prematurity outcome in infants with prethreshold retinopathy of prematurity and oxygen saturation >94% in room air: the high oxygen percentage in retinopathy of prematurity study. Pediatrcs. 2002;110(3):540-4.

The STOP-ROP multicenter study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized controlled trial. I: primary outcomes. Pediatrics. 2000;15(2)0: 295-310.

Ahmed AS, Muslima H, Anwar KS, Khan NZ, Chowdhury MA, Saha SK, et al. Retinopathy of prematurity in Bangladeshi neonate. J Trop Pediatr. 2008;54(5):333-9.

Akter S, Shirin M, Hossain MM. Retinopathy of prematurity: are we prepared to face the third epidemic? Bangladesh J Child Health. 2006;30:25-8.

Muhit MA, Shah SP, Gilbert CE, Foster A. Causes of severe visual impairment and blindness in Bangladesh: a study of 1935 children. Br J Ophthalmol. 2007;91(8):1000-4.

Chaudhari S, Patwardhan V, Vaidya U, Kadam S, Kamat A. Retinopathy of prematurity in a tertiary care centre-incidence, risk factors and outcome. Indian Pediatr. 2009;46(3):219-24.

Wheatley CM, Dickinson JL, Mackey DA, Craig JE, Sale MM. Retinopathy of prematurity: recent advances in our understanding. Arc Dis Child Fetal Neonate Ed. 2002;87(2):78-82.

Wright KW, Sami D, Thompson L, Ramanathan R, Joseph R. A physiologic reduced oxygen protocol decrease the incidence of threshold retinopathy of prematurity. Trans Am Ophthalmol Soc. 2006;104:78-84.

SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med J. 2010;362(21):1959-69.

Flyn JT, Bancalari E, Snyder ES, Goldberg RN, Feuer W, Cassady J, et al. A COHORT study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med. 199;89:77-92.

Hauspurg AK, Allred EN, Vanderveen DK, Chen M, Bednarek FJ, Cole C, at el. Blood gases and retinopathy of prematurity: the ELGAN study. Neonatology. 2011;99(2):104-11.

Teioh SL, Boo NY, Ong LC, Nyein MK, Lye MS. Duration of oxygen therapy and exchange transfusion as risk factors associated with retinopathy of prematurity in very low birth weight infants. Eye. 1995;9:733-7.

Rekha S, Battu RR. Retinopathy of prematurity: Incidence and risk factors. Indian Pediatr. 1996;33(10):999-1003.

Patil J, Deodhar J, Wagh S, Pandit AN. High risk factors for development of retinopathy of prematurity. Indian Pediatr. 1997;34(11):1024-7.

Guha DK, Guha R, Srivastava RD. Manual of Neonatal critical care medicine. 1st ed. New Delhi: Jaypee Brothers Medical Publisher; 2006.

Kinsey VE, Jacobus JT, Hemphill F. Retrolental fibroplasia: cooperative study of retrolental fibroplasias and the use of oxygen. Archiv Pediatr Adolesc Med. 1956;92(4):395.

Gilbert C, Foster A. Childhood blindness in the context of VISION 2020-the right to sight. Bull World Health Organ. 2001;79(3):227-32.






Original Research Articles